Department of Medicine
Faculty Profiles by Division

Division of Infectious Diseases

Faculty Profiles

[Return To Index page]
photo Sharon A. Riddler, MD

Infectious Diseases

Professor of Medicine

Associate Chief of Clinical Research

Co-Principal Investigator, Pitt-Ohio State Clinical Trials Unit

Member, AIDS Clinical Trials Group (ACTG) Executive Committee


Phone: 412-383-1675

Office: Keystone Bldg.
Keystone Bldg. 5th Floor
Pittsburgh, PA 15213
Phone: 412-383-1675
Fax: 412-383-2900
Administrative Assistant:
Ari Blackford-Rupp
Address: Keystone Bldg.
3520 Fifth Avenue, 5th Fl
Pittsburgh, PA 15213
Phone: 412-383-1675
Fax: 412-383-2900
Education and Training
BS, Marquette University, Milwaukee, WI, 1982
MD, Medical College of Wisconsin, Milwaukee, WI, 1986
MPH Epidemiology, University of Pittsburgh, 2002
Internship, University of Missouri, Kansas City, MO, 1987
Residency Training, University of Missouri, Kansas City, MO, 1990
Infectious Diseases Fellowship, University of Pittsburgh, Pittsburgh, PA, 1994
Research Interest
Dr. Riddler has more than 25 years of experience in clinical research funded by the NIH and industry. She is interested in all aspects of the clinical research process, including protocol development, implementation, and analysis of results. She is the Co-PI of the NIH/DAIDS-funded Pitt-OSU HIV/AIDS Clinical Trials Unit and Site Leader for the University of Pittsburgh Clinical Research Site (affiliated with both the AIDS Clinical Trials Group (ACTG) and the HIV Vaccine Trials Network (HVTN)). Dr. Riddler has been Chair or Co-Chair for several completed, ongoing, and planned network studies in the ACTG, MTN, and HVTN. Additionally she is PI or Co-PI for two ongoing U01-funded investigator-initiated clinical trials in HIV focused on therapeutic vaccines and immune-based therapies for chronic HIV infection. Dr. Riddler's group collaborates widely across the University of Pittsburgh to accomplish state-of-the-art clinical trials.
Clinical Interest
Dr. Riddler has cared for patients with HIV infection since 1992. She provides outpatient primary and specialty care to a panel of approximately 200 HIV-infected patients in the Pittsburgh AIDS Center for Treatment.
Educational Interest
Dr. Riddler participates in clinical education of ID fellows and Internal Medicine residents in the HIV clinic.
For my complete bibliography, Click Here.
Selected Publications:
Riddler SA, Para M, Benson CA, Mills A, Ramgopal M, DeJesus E, Brinson C, Cyktor J, Jacobs J, Koontz D, Mellors JW, Laird GM, Wrin T, Patel H, Guo S, Wallin J, Boice J, Zhang L, Humeniuk R, et. al. Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults with HIV-1. Clinical Infectious Diseases. 2021; 72(11): e815-e824.
Macatangay BJC, Jackson EK, Abebe KZ, Comer D, Cyktor J, Klamar-Blain C, Borowski L, Gillespie DG, Mellors JW, Rinaldo CR, Riddler SA. A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Hiv-Associated Chronic Inflammation. Journal Infectious Disease. 2019; 221(10): 1598-1606.
Riddler SA, Balkus JE, Parikh UM, Mellors JW, Akello C, Dabadhai S, Mhlanga F, Ramjee G, Mayo AJ, Livant E, Heaps AL, O'Rourke C, Baeten JM, for the MTN-015 and MTN-020/ASPIRE Study Teams. Clinical and virologic outcomes following initiation of antiretroviral therapy among seroconverters in the MTN-020/ASPIRE Phase III trial of the dapivirine vaginal ring. Clinical Infectious Disease. 2018; 69(3): 523-529.
Riddler SA, Zheng L, Durand CM, Ritz J, Koup RA, Ledgerwood J, Bailer RT, Koletar SL, Eron JJ, Keefer MC, Macatangay BJC, Cyktor JC, Mellors JW, for the AIDS Clinical Trials Group A5342 Protocol Team. Randomized clinical trial to assess the impact of the broadly-neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ART. Open Forum Infectious Disease. 2018; 5(10): ofy242.
Macatangay BJ, Riddler SA, Wheeler ND, Spindler J, Lawani M, Hong F, Buffo MJ, Whiteside TL, Kearney MF, Mellors JW, Rinaldo CR. Therapeutic vaccination with dendritic cells loaded with autologous HIV Type 1-infected apoptotic cells. Journal Infectious Disease. 2016; 213: 556-60.
Riddler SA, Aga E, Bosch RJ, Bastow B, Bedison M, Vagratian D, Vaida F, Eron JJ, Gandhi RT, Mellors JW, ACTG A5276s Protocol Team. Continued slow decay of residual plasma viremia level in HIV-1-infected adults receiving long term antiretroviral therapy. Journal Infectious Disease. 2016; 213(4): 556-60.
Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW. Class-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142. New England Journal of Medicine. 2008; 358: 2095-106.
Sponsored Research/Activities
Title: Native-like Envelope Trimer Therapeutic Vaccination for Induction of Broadly Neutralizing Antibodies to Facilitate HIV Functional Cure
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: U01 AI152969
Start Year: 2020
End Year: 2025
Title: Pitt-Ohio State - Georgetown Clinical Trials Unit
Role: Co-Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI069494
Start Year: 2013
End Year: 2020
Title: Aids Clinical Trial Group (ACTG) Protocol Funds
Role: Site Investigator
Funding Agency: University of California Los Angeles/ National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI068636
Start Year: 2018
End Year: 2019